Pancreatic Cancer Research

ResearcherThe University of SydneyActive in the last 2 years

Stephen John Clarke

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5817-1222; OpenAlex author ID A5074842604. Sources: OpenAlex.

Their work

Papers
17 (first author 2, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
84
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: 3 papers · 2022: 2 papers · 2023: 2 papers · 2024: none · 2025: 2 papers · 2026: 1 paper

Papers 17

  1. Validation of the PANAMA Score in Patients With Pancreatic Ductal Adenocarcinoma Undergoing Distal Pancreatectomy. Co-author DOI 10.1111/ans.70999↗
  2. SPAN-C: Results of a Phase II Clinical Trial of Stereotactic Body Radiotherapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1111/1754-9485.13874↗
  3. Promising biomarker panel to monitor therapeutic efficacy of neoadjuvant chemotherapy in pancreatic cancer patients. Co-author DOI 10.1111/eci.14341↗
  4. The role of diagnostic, prognostic, and predictive biomarkers in the management of early pancreatic cancer. First author DOI 10.1007/s00432-023-05149-4↗
  5. The Prognostic and Predictive Role of the Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Lymphocyte-to-Monocyte Ratio (LMR) as B… Last author DOI 10.3390/jcm12051989↗
  6. The role of staging laparoscopy in pancreatic adenocarcinoma and its effect on patients' survival. Co-author DOI 10.1186/s12957-022-02803-y↗
  7. The Right Treatment Strategy for the Right Patient: A Biomarker-Driven Approach to Neoadjuvant vs. Surgery-First Management of Resectable and Borderline Resect… Co-author DOI 10.3390/cancers14153620↗
  8. Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy. Co-author DOI 10.1016/j.ejso.2021.04.005↗
  9. A Critical Assessment of Postneoadjuvant Therapy Pancreatic Cancer Regression Grading Schemes With a Proposal for a Novel Approach. Co-author DOI 10.1097/pas.0000000000001601↗
  10. Optimal Upfront Treatment in Surgically Resectable Pancreatic Cancer Candidates: A High-Volume Center Retrospective Analysis. Co-author DOI 10.3390/jcm10122700↗
  11. Evaluation of Fluorodeoxyglucose Positron Emission Tomography Scanning in the Neoadjuvant Therapy Paradigm in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001472↗
  12. Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study. Co-author DOI 10.1016/j.ejso.2018.10.050↗
  13. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. Co-author DOI 10.1093/jnci/djz073↗
  14. Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. Co-author DOI 10.1136/gutjnl-2017-315144↗
  15. Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high volume r… Last author DOI 10.1016/j.ejso.2017.06.012↗
  16. Pathogenic PALB2 mutation in metastatic pancreatic adenocarcinoma and neuroendocrine tumour: A case report. First author DOI 10.3892/mco.2015.533↗
  17. Adverse tumor biology associated with mesenterico-portal vein resection influences survival in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1245/s10434-014-3554-4↗

Closest collaborators

The 25 strongest of 84 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jaswinder Singh Samra · 17 shared papers, 2014–2026 · strength 2.15
  2. Nick Pavlakis · 15 shared papers, 2014–2026 · strength 2.04
  3. Anubhav Mittal · 13 shared papers, 2017–2026 · strength 1.94
  4. Anthony James Gill · 14 shared papers, 2014–2026 · strength 1.68
  5. Sumit Sahni · 6 shared papers, 2021–2025 · strength 0.96
  6. Sarah Maloney · 5 shared papers, 2021–2025 · strength 0.82
  7. Angela S. Y. Chou · 5 shared papers, 2018–2026 · strength 0.81
  8. George Hruby · 6 shared papers, 2017–2025 · strength 0.74
  9. Malinda Itchins · 6 shared papers, 2017–2023 · strength 0.65
  10. Christopher Bahdah Nahm · 6 shared papers, 2017–2022 · strength 0.63
  11. Emily K. Colvin · 4 shared papers, 2019–2023 · strength 0.57
  12. David Lok Hang Chan · 4 shared papers, 2015–2025 · strength 0.55
  13. Nigel Balfour Jamieson · 4 shared papers, 2019–2021 · strength 0.34
  14. Krishna Kotecha · 1 shared paper, 2026 · strength 0.28
  15. Simeng Li · 1 shared paper, 2026 · strength 0.28
  16. Hiro Masuda · 1 shared paper, 2026 · strength 0.28
  17. Terence C. Chua · 3 shared papers, 2017–2021 · strength 0.26
  18. Sooin Byeon · 1 shared paper, 2025 · strength 0.23
  19. Josef Gillson · 1 shared paper, 2025 · strength 0.23
  20. Joseph C. Y. Chan · 1 shared paper, 2025 · strength 0.22
  21. Jeremy Booth · 1 shared paper, 2025 · strength 0.22
  22. Maxwell A. Jambor · 1 shared paper, 2022 · strength 0.15
  23. Asanka Rohan Wijetunga · 1 shared paper, 2021 · strength 0.11
  24. Lorraine A. Chantrill · 2 shared papers, 2015–2018 · strength 0.10
  25. Andrew H. Ko · 1 shared paper, 2019 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.